Kimberly L Johung1, Norman Yeh1, Neil B Desai1, Terence M Williams1, Tim Lautenschlaeger1, Nils D Arvold1, Matthew S Ning1, Albert Attia1, Christine M Lovly1, Sarah Goldberg1, Kathryn Beal1, James B Yu1, Brian D Kavanagh1, Veronica L Chiang1, D Ross Camidge1, Joseph N Contessa2. 1. Kimberly L. Johung, Sarah Goldberg, James B. Yu, Veronica L. Chiang, and Joseph N. Contessa, Yale University School of Medicine, New Haven, CT; Norman Yeh, Brian D. Kavanagh, and D. Ross Cambidge, University of Colorado Comprehensive Cancer Center, Aurora, CO; Neil B. Desai and Kathryn Beal, Memorial Sloan Kettering Cancer Center, New York, NY; Terence M. Williams and Tim Lautenschlaeger, Ohio State University, Columbus, OH; Nils D. Arvold, Dana-Farber/Brigham and Women's Hospital, Boston, MA; and Matthew S. Ning, Albert Attia, and Christine M. Lovly, Vanderbilt University School of Medicine, Nashville, TN. 2. Kimberly L. Johung, Sarah Goldberg, James B. Yu, Veronica L. Chiang, and Joseph N. Contessa, Yale University School of Medicine, New Haven, CT; Norman Yeh, Brian D. Kavanagh, and D. Ross Cambidge, University of Colorado Comprehensive Cancer Center, Aurora, CO; Neil B. Desai and Kathryn Beal, Memorial Sloan Kettering Cancer Center, New York, NY; Terence M. Williams and Tim Lautenschlaeger, Ohio State University, Columbus, OH; Nils D. Arvold, Dana-Farber/Brigham and Women's Hospital, Boston, MA; and Matthew S. Ning, Albert Attia, and Christine M. Lovly, Vanderbilt University School of Medicine, Nashville, TN. joseph.contessa@yale.edu.
Abstract
PURPOSE: We performed a multi-institutional study to identify prognostic factors and determine outcomes for patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and brain metastasis. PATIENTS AND METHODS: A total of 90 patients with brain metastases from ALK-rearranged NSCLC were identified from six institutions; 84 of 90 patients received radiotherapy to the brain (stereotactic radiosurgery [SRS] or whole-brain radiotherapy [WBRT]), and 86 of 90 received tyrosine kinase inhibitor (TKI) therapy. Estimates for overall (OS) and intracranial progression-free survival were determined and clinical prognostic factors were identified by Cox proportional hazards modeling. RESULTS: Median OS after development of brain metastases was 49.5 months (95% CI, 29.0 months to not reached), and median intracranial progression-free survival was 11.9 months (95% CI, 10.1 to 18.2 months). Forty-five percent of patients with follow-up had progressive brain metastases at death, and repeated interventions for brain metastases were common. Absence of extracranial metastases, Karnofsky performance score ≥ 90, and no history of TKIs before development of brain metastases were associated with improved survival (P = .003, < .001, and < .001, respectively), whereas a single brain metastasis or initial treatment with SRS versus WBRT were not (P = .633 and .666, respectively). Prognostic factors significant by multivariable analysis were used to describe four patient groups with 2-year OS estimates of 33%, 59%, 76%, and 100%, respectively (P < .001). CONCLUSION: Patients with brain metastases from ALK-rearranged NSCLC treated with radiotherapy (SRS and/or WBRT) and TKIs have prolonged survival, suggesting that interventions to control intracranial disease are critical. The refinement of prognosis for this molecular subtype of NSCLC identifies a population of patients likely to benefit from first-line SRS, close CNS observation, and treatment of emergent CNS disease.
PURPOSE: We performed a multi-institutional study to identify prognostic factors and determine outcomes for patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and brain metastasis. PATIENTS AND METHODS: A total of 90 patients with brain metastases from ALK-rearranged NSCLC were identified from six institutions; 84 of 90 patients received radiotherapy to the brain (stereotactic radiosurgery [SRS] or whole-brain radiotherapy [WBRT]), and 86 of 90 received tyrosine kinase inhibitor (TKI) therapy. Estimates for overall (OS) and intracranial progression-free survival were determined and clinical prognostic factors were identified by Cox proportional hazards modeling. RESULTS: Median OS after development of brain metastases was 49.5 months (95% CI, 29.0 months to not reached), and median intracranial progression-free survival was 11.9 months (95% CI, 10.1 to 18.2 months). Forty-five percent of patients with follow-up had progressive brain metastases at death, and repeated interventions for brain metastases were common. Absence of extracranial metastases, Karnofsky performance score ≥ 90, and no history of TKIs before development of brain metastases were associated with improved survival (P = .003, < .001, and < .001, respectively), whereas a single brain metastasis or initial treatment with SRS versus WBRT were not (P = .633 and .666, respectively). Prognostic factors significant by multivariable analysis were used to describe four patient groups with 2-year OS estimates of 33%, 59%, 76%, and 100%, respectively (P < .001). CONCLUSION:Patients with brain metastases from ALK-rearranged NSCLC treated with radiotherapy (SRS and/or WBRT) and TKIs have prolonged survival, suggesting that interventions to control intracranial disease are critical. The refinement of prognosis for this molecular subtype of NSCLC identifies a population of patients likely to benefit from first-line SRS, close CNS observation, and treatment of emergent CNS disease.
Authors: Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou Journal: Lancet Oncol Date: 2014-08-18 Impact factor: 41.316
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: Gregory N Gan; Andrew J Weickhardt; Benjamin Scheier; Robert C Doebele; Laurie E Gaspar; Brian D Kavanagh; D Ross Camidge Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-22 Impact factor: 7.038
Authors: Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: Kimberly L Johung; Xiaopan Yao; Fangyong Li; James B Yu; Scott N Gettinger; Sarah Goldberg; Roy H Decker; Judith A Hess; Veronica L Chiang; Joseph N Contessa Journal: Clin Cancer Res Date: 2013-07-29 Impact factor: 12.531
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316
Authors: Scott C Lester; Glen B Taksler; J Griff Kuremsky; John T Lucas; Diandra N Ayala-Peacock; David M Randolph; J Daniel Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Cancer Date: 2013-10-21 Impact factor: 6.921
Authors: F Couñago; A Rodríguez; P Calvo; J Luna; J L Monroy; B Taboada; V Díaz; N Rodríguez de Dios Journal: Clin Transl Oncol Date: 2016-04-22 Impact factor: 3.405
Authors: Mustafa S Ascha; Kaitlyn Funk; Andrew E Sloan; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Clin Exp Metastasis Date: 2019-11-08 Impact factor: 5.150